Appili Therapeutics Reports Fiscal Year 2026 Financial and Operational Results
Appili Therapeutics Inc. shared its financial and operational results for fiscal year 2026, highlighting the growing momentum for its LIKMEZ® (ATI-1501) in the U.S. market and the backing of a $40 million NIAID award for advancing VXV-01 through Phase 1 trials. This significant funding and commercial traction underscore the company's progress in addressing infectious diseases, potentially reshaping the landscape for medical countermeasures. The developments are crucial as they signal a step forward in tackling critical health challenges with innovative drug solutions.
Original Source
Read the full article at Financialpost →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.